Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
46 /100
MEDIUM RISK
Score updated Oct 13, 2026

LCTX — Lineage Cell Therapeutics, Inc. Dilution Risk Tracker

Track LCTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track LCTX — Get alerts when the score changes →

As of October 13, 2026, Lineage Cell Therapeutics, Inc. (LCTX) has a DilutionWatch DilutionScore of 46/100, rated MEDIUM dilution risk. Lineage Cell Therapeutics, Inc. has a market capitalization of $241.27M, 252.91M shares outstanding, 132 institutional holders tracked. Stored dilution-related fields include shelf registration capacity of $100.00M, ATM program capacity of $37.42M, 35.18M outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
67
💰 Cash Runway
25
📊 Float Risk
27
⚠️ Warrant Exposure
50
🔄 Convertible Debt
15

Dilution Forecast

⛅
Watch
Minor dilution signals detected
model est. 31%
💰 Capital Raise model 38%
• Active shelf registration ($100M, 41% of market cap)
• Active ATM program with $37M remaining capacity
🔄 Reverse Split model est. 30%
• 50-day avg $1.46 approaching $1 threshold
📜 Warrant Exercise model 15%
• Warrant overhang: 13.9% of shares outstanding
🔔 Track LCTX — Get forecast alerts →

Market Data

Market Cap$241.27M
Shares Outstanding252.91M
Float187.28M
Cash$50.83M
DebtN/A
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore46/100DilutionWatch score record
Shares Outstanding252.91MVerified float table or market cache
Public Float187.28MVerified float table or market cache
Market Cap$241.27MMarket data cache
Cash Runway20.3 monthsDilutionWatch score inputs
Shelf Capacity$100.00MSEC-derived dilution fields
ATM Capacity$37.42MSEC-derived dilution fields
Outstanding Warrants35.18MSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 1, 424B5 1, 8-K 1, EFFECT 1, S-3 1, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 23.2% shares (2026Q1 vs prior)
132 institutional holders · 125.87M shares
#1 BROADWOOD CAPITAL INC 49.56M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 16.64M shares
#3 Defender Capital, LLC. 6.73M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest29.09M
Days to Cover15.8
% of Float15.5%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-08-06
xbrl XBRL CONVERTIBLE 2019-03-14
EFFECT EFFECT 2026-03-23
4 INSIDER TRANSACTION 2026-03-12
S-3 SHELF 2026-03-11
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual LCTX Dilution Snapshot

Lineage Cell Therapeutics, Inc. (LCTX) has a DilutionScore of 46/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

LCTX's DilutionScore is currently 46/100 (Medium risk), with 2 score changes tracked over 89 days. The score deteriorated from 48/100 (Medium risk).

Period Score Risk Level Duration
Aug 22 – Oct 13, 202646/100MEDIUM53 days
Aug 14 – Aug 21, 202648/100MEDIUM7 days
Jul 16 – Aug 13, 202646/100MEDIUM29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

LCTX shares outstanding have increased 8.2% from 230.33M (Mar 2026) to 249.30M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 14, 2026249.30M187.28M▲ 0.08%
May 11, 2026249.30M187.12M▲ 0.03%
Mar 12, 2026230.33M187.08M▲ 0.93%
Mar 07, 2026230.33M185.35M▲ 8.14%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track LCTX Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment LCTX files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking LCTX — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for LCTX
LCTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.